Taylor Dawson, MD
Interventional Cardiology · Traverse City, MINPI 1396126595
Payments from drug & device makers
Across 15 payments — averaging $229.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Boston Scientific$169
- Terumo Medical Corporation$141
- W. L. Gore & Associates, Inc.$129
- Cathworks, Inc.$84
- Penumbra, Inc.$63
- plus $114 from 3 others
What the payments were for
- Grants$2,66778%
- Food & beverage$76922%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 4 | $2,736 |
| Boston Scientific | 2 | $169 |
| Terumo Medical Corporation | 2 | $141 |
| W. L. Gore & Associates, Inc. | 1 | $129 |
| Cathworks, Inc. | 1 | $84 |
| Penumbra, Inc. | 1 | $63 |
| Abiomed | 2 | $56 |
| Shockwave Medical, Inc | 1 | $30 |
| Abbott | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESOLUTE ONYX$2,667
- GORE CARDIOFORM Septal Occluder$129
- GlideWire$120
How this compares
$3,436 in reported general payments places this provider in the 25th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 254 | $261,678 |
| XareltoRivaroxaban | 43 | $40,610 |
| Repatha SyringeEvolocumab | 29 | $26,260 |
| JardianceEmpagliflozin | 20 | $12,807 |
| Repatha SureclickEvolocumab | 12 | $11,617 |
| Praluent PenAlirocumab | 12 | $5,703 |
| Metoprolol Succinate | 329 | $5,359 |
| Atorvastatin Calcium | 312 | $4,747 |
| Bumetanide | 57 | $2,421 |
| Ranolazine ErRanolazine | 29 | $2,311 |
| Rosuvastatin Calcium | 114 | $1,951 |
| Ezetimibe | 96 | $1,925 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $1,907 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 99 | $1,775 |
| Losartan Potassium | 133 | $1,729 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Traverse City
- Amir KakiDetroit$2.3M
- William MerhiGrand Rapids$2M
- Shukri DavidSouthfield$1.6M
- Qaiser ShafiqSouthgate$1.3M
- Marcel ZughaibSouthfield$1.2M
- Jason RicciPetoskey$1.1M
- Khaldoon AlaswadDetroit$1.1M
- Paul GrossmanAnn Arbor$1.1M
- Tamam MohamadDetroit$960K
- Harry ColferPetoskey$940K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.